EA019151B1 - Конъюгаты синтетических агонистов tlr и их применение - Google Patents

Конъюгаты синтетических агонистов tlr и их применение Download PDF

Info

Publication number
EA019151B1
EA019151B1 EA200901078A EA200901078A EA019151B1 EA 019151 B1 EA019151 B1 EA 019151B1 EA 200901078 A EA200901078 A EA 200901078A EA 200901078 A EA200901078 A EA 200901078A EA 019151 B1 EA019151 B1 EA 019151B1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
agonist
substituted
compound
conjugates
Prior art date
Application number
EA200901078A
Other languages
English (en)
Russian (ru)
Other versions
EA200901078A1 (ru
Inventor
Деннис А. Карсон
Ховард Б. Коттам
Вольфганг Врасидло
Кристина С.Н. Ву
Грегори А. Дэниелс
Original Assignee
Дзе Регентс Оф Дзе Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Регентс Оф Дзе Юниверсити Оф Калифорния filed Critical Дзе Регентс Оф Дзе Юниверсити Оф Калифорния
Publication of EA200901078A1 publication Critical patent/EA200901078A1/ru
Publication of EA019151B1 publication Critical patent/EA019151B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EA200901078A 2007-02-07 2008-02-07 Конъюгаты синтетических агонистов tlr и их применение EA019151B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88869907P 2007-02-07 2007-02-07
PCT/US2008/001631 WO2008115319A2 (en) 2007-02-07 2008-02-07 Conjugates of synthetic tlr agonists and uses therefor

Publications (2)

Publication Number Publication Date
EA200901078A1 EA200901078A1 (ru) 2010-06-30
EA019151B1 true EA019151B1 (ru) 2014-01-30

Family

ID=39766655

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901078A EA019151B1 (ru) 2007-02-07 2008-02-07 Конъюгаты синтетических агонистов tlr и их применение

Country Status (18)

Country Link
US (3) US8357374B2 (enExample)
EP (2) EP2125007B9 (enExample)
JP (2) JP5425642B2 (enExample)
KR (1) KR20090109121A (enExample)
CN (1) CN101790380B (enExample)
AU (1) AU2008227128B2 (enExample)
BR (1) BRPI0807196A2 (enExample)
CA (1) CA2677733A1 (enExample)
DK (1) DK2510946T3 (enExample)
EA (1) EA019151B1 (enExample)
ES (2) ES2552471T3 (enExample)
HU (1) HUE025555T2 (enExample)
IL (1) IL200240A (enExample)
PL (2) PL2125007T3 (enExample)
PT (1) PT2510946E (enExample)
SI (1) SI2510946T1 (enExample)
WO (1) WO2008115319A2 (enExample)
ZA (1) ZA200906094B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2684644C1 (ru) * 2013-12-09 2019-04-11 Юсб Байофарма Спрл Производные пурина в качестве модуляторов активности tnf

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007024707A2 (en) 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists
AU2007257423B8 (en) 2006-05-31 2012-02-16 The Regents Of The University Of California Purine analogs
EP2125007B9 (en) 2007-02-07 2014-04-16 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
WO2009049365A1 (en) * 2007-10-15 2009-04-23 Cooperative Research Centre For Asthma A method of prophylaxis and agents for use therein
CN102088974A (zh) * 2008-02-07 2011-06-08 加利福尼亚大学校务委员会 用tlr7活化剂对膀胱疾病的治疗
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
WO2010093436A2 (en) * 2009-02-11 2010-08-19 Carson Dennis A Toll-like receptor modulators and treatment of diseases
US8629151B2 (en) * 2009-05-27 2014-01-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
SG10201406813RA (en) 2009-10-22 2014-11-27 Gilead Sciences Inc Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
CN103221067B (zh) * 2010-04-30 2016-01-06 泰勒麦迪克斯公司 磷脂药物类似物
AU2011247359A1 (en) * 2010-04-30 2012-11-15 Telormedix Sa Methods for inducing an immune response
WO2011139348A2 (en) * 2010-04-30 2011-11-10 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
PL2575876T3 (pl) 2010-05-26 2018-07-31 Selecta Biosciences, Inc. Szczepionki poliwalentne z syntetycznymi nanonośnikami
US20120083473A1 (en) 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
RS62254B1 (sr) 2011-04-08 2021-09-30 Janssen Sciences Ireland Unlimited Co Derivati pirimidina za tretman virusnih infekcija
JP6415979B2 (ja) * 2011-06-03 2018-10-31 スリーエム イノベイティブ プロパティズ カンパニー ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体
EP2717919B1 (en) 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
WO2013019658A2 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
SG11201401244TA (en) 2011-11-09 2014-09-26 Janssen R & D Ireland Purine derivatives for the treatment of viral infections
US9107904B2 (en) 2012-04-05 2015-08-18 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
HUE030685T2 (en) 2012-07-13 2017-05-29 Janssen Sciences Ireland Uc Macrocyclic purines for treating viral infections
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014052828A1 (en) 2012-09-27 2014-04-03 The Regents Of The University Of California Compositions and methods for modulating tlr4
WO2014056953A1 (en) 2012-10-10 2014-04-17 Janssen R&D Ireland Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
CN105061567B (zh) * 2012-10-10 2021-07-20 深圳大学 免疫受体调节剂偶联体及其制备方法和应用、制备其的偶联前体以及合成偶联前体的化合物
MY171115A (en) 2012-11-16 2019-09-26 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
UA118751C2 (uk) 2013-02-21 2019-03-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні 2-амінопіримідину для лікування вірусних інфекцій
US9649373B2 (en) 2013-02-25 2017-05-16 The Scripps Institute Neoseptins: small molecule adjuvants
JP6348967B2 (ja) * 2013-03-14 2018-06-27 ワン、ロンフ 制御性ｔ細胞機能を調節する方法および組成物
WO2014144365A1 (en) * 2013-03-15 2014-09-18 University Of Maryland, College Park Nano-liposomal formulations and methods of use
AU2014242954B2 (en) 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
MX365848B (es) 2013-05-24 2019-06-17 Janssen Sciences Ireland Uc Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales.
AU2014301089B2 (en) 2013-06-27 2018-10-04 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
AU2014298540B2 (en) 2013-07-30 2018-08-09 Janssen Sciences Ireland Uc Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
US20160199499A1 (en) * 2013-08-16 2016-07-14 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
CA2936375A1 (en) 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Compounds and compositions for treating her2 positive tumors
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)
FI4001311T3 (fi) 2014-07-09 2026-01-27 Birdie Biopharmaceuticals Inc Pd-l1/pd-1-vasta-aineiden yhdistelmiä kasvaimien hoitoon
CN105440135A (zh) 2014-09-01 2016-03-30 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CA2957372C (en) 2014-08-06 2019-07-23 The Scripps Research Institute Tlr-independent small molecule adjuvants
CN110759916B (zh) * 2014-08-15 2021-02-19 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
US10034901B2 (en) 2015-01-22 2018-07-31 University Of Massachusetts Cancer immunotherapy
US10682314B2 (en) 2015-05-26 2020-06-16 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus
WO2016210241A1 (en) 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
EP3355933B1 (en) * 2015-09-29 2020-05-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
CN105311032B (zh) * 2015-11-09 2018-09-25 深圳大学 Tlr7激动剂与酪氨酸激酶抑制剂联用在制备抗肿瘤药物中的应用
CN105315281B (zh) * 2015-11-16 2017-04-19 深圳大学 化合物i和化合物ii及其制备方法和应用
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
MX2018013640A (es) * 2016-05-16 2019-08-01 Infectious Disease Res Inst Liposomas pegiladas y metodos de uso.
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
MA45539A (fr) 2016-07-01 2019-05-08 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines pour le traitement d'infections virales
WO2018013924A1 (en) 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
WO2018060317A1 (en) 2016-09-29 2018-04-05 Janssen Sciences Ireland Uc Pyrimidine prodrugs for the treatment of viral infections and further diseases
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
US11459568B2 (en) 2016-10-31 2022-10-04 University Of Massachusetts Targeting microRNA-101-3p in cancer therapy
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
JP2020513554A (ja) 2016-12-07 2020-05-14 プロジェニティ， インコーポレイテッド 胃腸管の検出方法、装置およびシステム
WO2018112223A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
JP7161760B2 (ja) * 2017-02-03 2022-10-27 国立大学法人東北大学 複素環化合物
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
CN110769827A (zh) 2017-06-23 2020-02-07 博笛生物科技有限公司 药物组合物
WO2019012107A1 (en) 2017-07-13 2019-01-17 Danmarks Tekniske Universitet CATIONIC LIPOSOMES
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US11814623B2 (en) 2018-01-30 2023-11-14 University Of Massachusetts Methods of treating a wound using epigenetic regulation
WO2019157087A1 (en) 2018-02-06 2019-08-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CN110317202B (zh) * 2018-03-30 2021-12-24 江苏恒瑞医药股份有限公司 氰基吡咯并杂芳基类衍生物、其制备方法及其在医药上的应用
CN108379591B (zh) * 2018-04-03 2022-03-29 深圳大学 免疫激动剂靶向化合物的合成及其应用
WO2019196918A1 (zh) * 2018-04-13 2019-10-17 罗欣药业(上海)有限公司 五元杂环并嘧啶类化合物、药物组合物及用途
EP3774806A1 (en) * 2018-04-13 2021-02-17 GlaxoSmithKline Biologicals SA Tlr7 and / or tlr8 agonists
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
US10765633B2 (en) * 2018-12-17 2020-09-08 Eisai R&D Management Co., Ltd Formulation comprising liposomes
CA3128386A1 (en) 2019-02-04 2020-08-13 Codiak Biosciences, Inc. Membrane protein scaffolds for exosome engineering
WO2020186229A1 (en) * 2019-03-14 2020-09-17 The Regents Of The University Of California Tlr4-tlr7 ligand formulations as vaccine adjuvants
US12453777B2 (en) 2019-03-20 2025-10-28 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
WO2020191377A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicle conjugates and uses thereof
MX2021011241A (es) 2019-03-21 2022-01-19 Codiak Biosciences Inc Vesiculas extracelulares para administracion de vacunas.
WO2020191369A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
EP3994158A1 (en) 2019-07-03 2022-05-11 Codiak BioSciences, Inc. Extracellular vesicles targeting t cells and uses thereof
US20230181758A1 (en) 2019-07-03 2023-06-15 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
KR20220066887A (ko) 2019-09-19 2022-05-24 덴마크스 텍니스케 유니버시테트 면역 자극 미셀 조성물
KR20220092654A (ko) 2019-09-25 2022-07-01 코디악 바이오사이언시즈, 인크. 세포외 소포 조성물
AU2020407871A1 (en) 2019-12-20 2022-06-30 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof
EP4097104A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
CN115151547A (zh) 2020-01-27 2022-10-04 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
EP4097102A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
KR20220132590A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
CN115279765B (zh) 2020-01-27 2024-11-12 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
US20230127326A1 (en) 2020-01-27 2023-04-27 Bristol-Myers Squibb Company C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115135655B (zh) 2020-01-27 2024-07-02 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
CN115151548A (zh) 2020-01-27 2022-10-04 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
EP4097105A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
US20250114445A1 (en) 2020-03-20 2025-04-10 Lonza Sales Ag Extracellular vesicles for therapy
US20230173059A1 (en) * 2020-05-15 2023-06-08 The Board Of Trustees Of The Leland Stanford Junior University Toll-like receptor (tlr) agonist nanoparticles and uses thereof
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
WO2021248133A1 (en) 2020-06-05 2021-12-09 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
CN111892648B (zh) * 2020-06-08 2022-08-26 中国科学院上海药物研究所 偶联tlr7激动剂的新型冠状病毒多肽疫苗及其应用
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
JP2023532717A (ja) 2020-07-02 2023-07-31 ヴィーブ ヘルスケア カンパニー 長期作用型抗レトロウイルス剤を用いたｈｉｖウイルス寛解の達成方法
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
US20240082389A1 (en) 2020-09-23 2024-03-14 Lonza Sales Ag Methods of producing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
US20230382886A1 (en) * 2020-10-21 2023-11-30 Univerza V Ljubljani Conjugated tlr7 and nod2 agonists
WO2022200553A2 (en) 2021-03-25 2022-09-29 Danmarks Tekniske Universitet Immune stimulating nanoparticle composition
WO2022246764A1 (zh) * 2021-05-27 2022-12-01 中科蓝华(广州)生物医药技术有限公司 一种分析cd303+树突状细胞亚群表型和功能的方法及试剂盒
CA3236949A1 (en) * 2021-11-03 2023-05-11 Adcentrx Therapeutics Inc. Drug conjugates and methods of preparing and using the same
CN116162088B (zh) * 2022-12-14 2025-03-11 江苏省农业科学院 一种Toll样受体7激动剂纳米颗粒及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
WO2005060966A1 (fr) * 2003-12-19 2005-07-07 Sanofi Pasteur Composition immunostimulante comprenant au moins un agoniste des recepteurs toll-like 7 ou du recepteur toll-like 8 et un agoniste du recepteur toll-like 4

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5736553A (en) 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
HU217080B (hu) 1990-10-05 1999-11-29 Minnesota Mining And Manufacturing Co. Új eljárás imidazo[4,5-c]kinolin-4-amin-származékok előállítására
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
DE19637209B4 (de) 1996-09-12 2006-12-14 Siemens Ag Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung
AU724042B2 (en) 1996-10-25 2000-09-07 Minnesota Mining And Manufacturing Company Immune response modifier compounds for treatment of TH2 mediated and related diseases
EP1685842A3 (en) 1996-10-25 2006-11-29 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
JPH10298181A (ja) 1997-04-25 1998-11-10 Sumitomo Pharmaceut Co Ltd タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤
DE69824632T2 (de) 1997-11-12 2005-06-09 Mitsubishi Chemical Corp. Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
ES2205573T3 (es) 1997-11-28 2004-05-01 Sumitomo Pharmaceuticals Company, Limited Nuevo compuestos heterociclicos.
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
ATE304852T1 (de) 1999-01-08 2005-10-15 3M Innovative Properties Co Zubereitungen, umfassend imiquimod oder andere immunantwort modifizierenden verbindungen, zur behandlung von zervikaler dysplasie
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
WO2001044259A1 (en) 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Purine derivatives
DE60028253T2 (de) 1999-12-17 2007-03-08 Ariad Pharmaceuticals, Inc., Cambridge Neue purine
JP2003519232A (ja) 2000-01-07 2003-06-17 ウニフェルジテーレ・インステリング・アントウェルペン プリン誘導体、その製造法およびその使用
US6733764B2 (en) 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
WO2002023186A2 (en) 2000-09-15 2002-03-21 Virco Bvba System and method for optimizing drug therapy for the treatment of diseases
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
WO2002030399A2 (en) 2000-10-11 2002-04-18 Johns Hopkins University Polymer controlled delivery of a therapeutic agent
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
ES2278016T3 (es) 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
ES2314042T3 (es) 2001-04-17 2009-03-16 Dainippon Sumitomo Pharma Co., Ltd. Derivados nuevos de adenina.
EP1572067A4 (en) 2001-05-18 2009-05-13 Sirna Therapeutics Inc CONJUGATES AND COMPOSITIONS FOR CELLULAR RELEASE
EP1401837B1 (en) 2001-06-29 2005-10-19 Cv Therapeutics, Inc. Purine derivatives as a2b adenosine receptor antagonists
CA2464031A1 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
GB0206461D0 (en) 2002-03-19 2002-05-01 Glaxo Group Ltd Improvements in vaccination
PT1545597E (pt) 2002-08-15 2010-12-29 3M Innovative Properties Co Composições imunoestimulantes e métodos de estimulação de uma resposta imunológica
JP4768263B2 (ja) 2002-09-27 2011-09-07 大日本住友製薬株式会社 新規アデニン化合物及びその用途
JP2004137157A (ja) 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
CN100387710C (zh) 2003-01-28 2008-05-14 上海三维生物技术有限公司 原发性癌和转移性癌相关的核酸
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20050059613A1 (en) 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
WO2005025583A2 (en) 2003-09-05 2005-03-24 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
JP2005089334A (ja) 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
BRPI0414533A (pt) 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
CN101031287A (zh) 2004-03-02 2007-09-05 麻省理工学院 纳米细胞药物递送系统
JPWO2005092892A1 (ja) * 2004-03-26 2008-02-14 大日本住友製薬株式会社 ８−オキソアデニン化合物
EP1728793B1 (en) 2004-03-26 2016-02-03 Sumitomo Dainippon Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
DK1819230T3 (da) 2004-12-07 2012-08-20 Univ Miami Erytrocytafledte mikropartikler som hæmostatiske midler til kontrol af hæmoragi og til behandling af blødningsforstyrrelser
JP2008533189A (ja) 2005-03-21 2008-08-21 フエルレル インターナショナル，ソシエダッド アノニマ １−置換１Ｈ−イミダゾ［４，５−ｃ］キノリン−４−アミン化合物及びそれらのための中間体を製造するための方法
US20070292418A1 (en) 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
WO2007024707A2 (en) 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists
JPWO2007034917A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規なアデニン化合物
JPWO2007034817A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
CN101340931A (zh) 2005-09-27 2009-01-07 科利制药公司 使用连接寡核苷酸调节tlr介导的免疫应答
US20070100146A1 (en) 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
AU2007257423B8 (en) 2006-05-31 2012-02-16 The Regents Of The University Of California Purine analogs
AU2007269557B2 (en) 2006-07-07 2013-11-07 Gilead Sciences, Inc. Modulators of toll-like receptor 7
TW200831104A (en) 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
EP2125007B9 (en) 2007-02-07 2014-04-16 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
AU2008271127C1 (en) 2007-06-29 2014-04-17 Gilead Sciences, Inc. Purine derivatives and their use as modulators of Toll-like receptor 7
WO2009052310A1 (en) 2007-10-16 2009-04-23 Cv Therapeutics, Inc A3 adenosine receptor antagonists
CN102088974A (zh) 2008-02-07 2011-06-08 加利福尼亚大学校务委员会 用tlr7活化剂对膀胱疾病的治疗
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
WO2010093436A2 (en) 2009-02-11 2010-08-19 Carson Dennis A Toll-like receptor modulators and treatment of diseases
SG10201406813RA (en) 2009-10-22 2014-11-27 Gilead Sciences Inc Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
CN103221067B (zh) 2010-04-30 2016-01-06 泰勒麦迪克斯公司 磷脂药物类似物
WO2011139348A2 (en) 2010-04-30 2011-11-10 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
AU2011247359A1 (en) 2010-04-30 2012-11-15 Telormedix Sa Methods for inducing an immune response
BR112013005134A2 (pt) 2010-09-01 2018-04-24 Novartis Ag adsorção de imunopotenciadores em sais metálicos insolúveis
US20120083473A1 (en) 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
WO2005060966A1 (fr) * 2003-12-19 2005-07-07 Sanofi Pasteur Composition immunostimulante comprenant au moins un agoniste des recepteurs toll-like 7 ou du recepteur toll-like 8 et un agoniste du recepteur toll-like 4

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JIN ET AL.: "Synthesis and immunostimulatory activity of 8-substituted amino 9-benzyladenines as potent Toll-like receptor 7 agonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 16, no. 17, 1 September 2006 (2006-09-01), pages 4559-4563, XP005593685, ISSN: 0960-894X, the whole document *
WILLE-REECE ULRIKE ET AL.: "HIV Gag protein conjugated to a toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8(+) T cell responses in nonhuman primates", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 42, October 2005 (2005-10), pages 15190-15194, XP002500309, ISSN: 0027-8424 page 15190, right-hand column, paragraph 3 - page 15191, left-hand column, paragraph 1 - page 15191, right-hand column, paragraph 4 - page 15194, right-hand column, paragraph 1 *
WU CHRISTINA С.N. ET AL.: "Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 10, March 2007 (2007-03), pages 3990-3995, XP002500310, ISSN: 0027-8424, the whole document *
ZAKS KAREN ET AL.: "Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 176, no. 12, 15 June 2006 (2006-06-15), pages 7335-7345, XP002485614, ISSN: 0022-1767, page 7336, left-hand column, paragraph 3 - right-hand column, paragraph 3 - page 7341, right-hand column, paragraph 2 - paragraph 3 - page 7342, right-hand column, paragraph 2 - page 7344, right-hand column, paragraph 1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2684644C1 (ru) * 2013-12-09 2019-04-11 Юсб Байофарма Спрл Производные пурина в качестве модуляторов активности tnf

Also Published As

Publication number Publication date
JP2010518082A (ja) 2010-05-27
WO2008115319A3 (en) 2009-03-05
HK1177886A1 (en) 2013-08-30
CA2677733A1 (en) 2008-09-25
EA200901078A1 (ru) 2010-06-30
SI2510946T1 (sl) 2015-12-31
HK1138767A1 (en) 2010-09-03
EP2510946A1 (en) 2012-10-17
US20130156807A1 (en) 2013-06-20
BRPI0807196A2 (pt) 2014-06-03
US9050376B2 (en) 2015-06-09
CN101790380B (zh) 2013-07-10
ZA200906094B (en) 2011-12-28
EP2125007B9 (en) 2014-04-16
AU2008227128B2 (en) 2012-12-06
PT2510946E (pt) 2015-11-23
IL200240A0 (en) 2010-04-29
DK2510946T3 (en) 2015-11-02
EP2125007B1 (en) 2014-01-08
US8790655B2 (en) 2014-07-29
US20140302120A1 (en) 2014-10-09
HUE025555T2 (en) 2016-02-29
PL2125007T3 (pl) 2014-07-31
US20120148660A1 (en) 2012-06-14
JP2013127004A (ja) 2013-06-27
WO2008115319A2 (en) 2008-09-25
CN101790380A (zh) 2010-07-28
ES2456964T9 (es) 2014-07-17
ES2552471T3 (es) 2015-11-30
AU2008227128A1 (en) 2008-09-25
PL2510946T3 (pl) 2015-12-31
ES2456964T3 (es) 2014-04-24
IL200240A (en) 2014-04-30
KR20090109121A (ko) 2009-10-19
US8357374B2 (en) 2013-01-22
JP5425642B2 (ja) 2014-02-26
EP2510946B1 (en) 2015-08-05
EP2125007A2 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
EA019151B1 (ru) Конъюгаты синтетических агонистов tlr и их применение
JP2014129425A (ja) Ｔｌｒ７活性化物質による膀胱の疾患の治療
US20130202629A1 (en) Uses of phospholipid conjugates of synthetic tlr7 agonists
JP2013040209A (ja) Ｔｌｒアゴニスト
CN102439011A (zh) Toll样受体调节剂和疾病的治疗
HK1177886B (en) Conjugates of synthetic tlr agonists and uses therefor
HK1138767B (en) Conjugates of synthetic tlr agonists and uses therefor
HK1126114A (en) Tlr agonists